![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
University of Aarhus Skejby Hospital Aarhus University Hospital Forskningsrådet for Sundhed og Sygdom |
---|---|
Information provided by: | University of Aarhus |
ClinicalTrials.gov Identifier: | NCT00652379 |
The purpose of this study is to investigate if co-treatment of acromegalic patients, who beforehand are considered well-controlled on SA monotherapy, with pegvisomant and SA will improve insulin sensitivity and glucose tolerance, and if these effects of co-treatment can be obtained at a neutral cost as compared to SA mono therapy.
Second to investigate body composition, substrate metabolism, symptoms, intrahepatic and intramyocellular fat.
Condition | Intervention |
---|---|
Acromegaly Insulin Resistance Impaired Glucose Tolerance |
Drug: Pegvisomant Drug: Somatostatin analog (Lanreotid or Octreotid) |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Co-Treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-Responsive Acromegalic Patients: Impact on Insulin Sensitivity, Glucose Tolerance, and Pharmacoeconomics |
Estimated Enrollment: | 30 |
Study Start Date: | June 2008 |
Estimated Study Completion Date: | August 2009 |
Estimated Primary Completion Date: | August 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Co-treatment with Pegvisomant and a somatostatin-analog
|
Drug: Pegvisomant
Pegvisomant s.c 15 mg 2 times a week
Drug: Somatostatin analog (Lanreotid or Octreotid)
Study arm 2: usual dosage of a somatostatin analog Study arm 1: half dosage of somatostatin analog
|
2: Active Comparator
Somatostatin analog
|
Drug: Somatostatin analog (Lanreotid or Octreotid)
Study arm 2: usual dosage of a somatostatin analog Study arm 1: half dosage of somatostatin analog
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jens Otto L. Jørgensen, MD Professor | 89492505 ext +45 | joj@ki.au.dk |
Contact: Michael Madsen, MD | 89492171 ext +45 | michael.madsen@ki.au.dk |
Denmark, Aarhus | |
Department of Endocrinology, Aarhus University Hospital | Recruiting |
Aarhus C, Aarhus, Denmark, 8000 | |
Principal Investigator: Jens Otto L. Jørgensen, MD Professor | |
Sub-Investigator: Michael Madsen, MD |
Principal Investigator: | Jens Otto L. Jørgensen, MD Professor | Department of Endocrinology, Aarhus University Hospital |
Responsible Party: | Department of endocrinology, Aarhus University Hospital ( Jens Otto L. Jørgensen, MD., Professor ) |
Study ID Numbers: | GH-2007-228, M-20070193, 2612-3602, 2008-38/22246-2, 2007-41-1082, 2007-005244-25 |
Study First Received: | March 26, 2008 |
Last Updated: | December 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00652379 |
Health Authority: | Denmark: Danish Dataprotection Agency; Denmark: Danish Medicines Agency; Denmark: The Danish National Committee on Biomedical Research Ethics; Denmark: The Regional Committee on Biomedical Research Ethics |
Acromegaly Insulin sensitivity Glucose tolerance Body composition Growth Hormone |
Bone Diseases, Endocrine Hypothalamic Diseases Metabolic Diseases Pituitary Diseases Glucose Intolerance Central Nervous System Diseases Endocrine System Diseases Brain Diseases Bone Diseases Somatostatin |
Insulin Hyperinsulinism Hyperglycemia Musculoskeletal Diseases Endocrinopathy Insulin Resistance Metabolic disorder Glucose Metabolism Disorders Acromegaly |
Hyperpituitarism Physiological Effects of Drugs Nervous System Diseases |
Hormones, Hormone Substitutes, and Hormone Antagonists Hormones Pharmacologic Actions |